Meyka Pro banner
Ocumension Therapeutics

Ocumension Therapeutics (1477.HK) Stock Competitors & Peer Comparison

See (1477.HK) competitors and their performances in Stock Market.

1477.HKHKSE
HealthcareBiotechnology
HK$5.82
HK$0.39(6.28%)
Hong Kong Market is Open · 14:24

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1477.HKHK$5.82-6.28%4.8B-25.78-HK$0.23N/A
4332.HKHK$1,850.00+0.00%998.5B45.81HK$40.38N/A
6160.HKHK$194.60+0.83%265B88.84HK$2.21N/A
2269.HKHK$39.22+1.03%160.9B30.39HK$1.28N/A
1801.HKHK$91.65-0.54%160.6B169.64HK$0.54N/A
6990.HKHK$525.00+2.64%120.6B-256.32-HK$2.02N/A
9926.HKHK$104.90+10.89%91B-73.72-HK$1.34N/A
3347.HKHK$38.00+1.23%46.3B39.06HK$0.98+0.38%
1530.HKHK$17.64+4.26%43.2B4.50HK$3.84+1.45%
6821.HKHK$119.20-2.61%42.9B38.98HK$3.05+1.26%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1477.HK vs 4332.HK Comparison July 2026

1477.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1477.HK stands at 4.8B. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 1477.HK is priced at HK$5.82, while 4332.HK trades at HK$1,850.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1477.HK currently has a P/E ratio of -25.78, whereas 4332.HK's P/E ratio is 45.81. In terms of profitability, 1477.HK's ROE is -0.04%, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 1477.HK is more volatile compared to 4332.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1477.HK.Check 4332.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions